6-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose
• 英文别名: (2S,3S,4S,5S,6R)-6-[[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
• 化学式: C₁₂H₂₂O₁₁
• 分子量: 342.3
• InChiKey: DLRVVLDZNNYCBX-ONPLHCRPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  190
• 氢给体数：
  8
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  、 、 、 6-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose 、 3,3'-Dithiobis(sulfosuccinimidylpropionate) 、 三羟甲基氨基甲烷 、 阿霉素 反应 4.0h， 生成 O-β-D-mannopyranosyl-(1->4)-D-mannopyranose
  参考文献：
  名称：

  Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome

  摘要：

  本发明的目的是提供一种具有糖链结合的脂质体，该糖链具有特异性结合各种组织细胞表面存在的各种凝集素（糖链识别蛋白），从而能够实际区分体内的细胞和组织，从而有效地传递药物或基因。

  公开号：

  US20070160657A1

文献信息

• Sugar-modified liposome and products comprising the liposome
  申请人：Yamazaki Noboru

  公开号：US20060193906A1

  公开（公告）日：2006-08-31

  The present invention provides a sugar-modified liposome having a sugar chain bonded to its membrane surface, preferably through a linker protein, and having excellent absorption qualities, particularly in the intestine. The molecular structure and quantity of the sugar chain is selectively varied to allow the liposome to be delivered in a targeted manner to selected cells and tissues. The liposome is applicable to medicinal drugs, cosmetics and other various products in the medical/pharmaceutical fields, and it is especially useful in a therapeutic drug delivery system that recognizes target cells and tissues, such as cancer cells, and in the delivery of drugs or genes locally to a selected region, or in a diagnostic cell/tissue sensing probe.

  本发明提供了一种糖基修饰脂质体，其具有糖链与其膜表面结合，优选通过连接蛋白质进行结合，并具有出色的吸收特性，特别是在肠道中。糖链的分子结构和数量可选择性地变化，以使脂质体以定向方式传递到选定的细胞和组织。该脂质体适用于医药、化妆品和其他医药领域的各种产品，特别是在识别靶细胞和组织（如癌细胞）的治疗药物传递系统中非常有用，以及在将药物或基因局部递送到选定区域或在诊断细胞/组织感应探针中使用。
• MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
  申请人：Aimmune Therapeutics, Inc.

  公开号：EP2968529B1

  公开（公告）日：2020-08-05
• Cellobiose Phosphorylase
  申请人：Pfeifer & Langen GmbH & Co. KG

  公开号：US20180216086A1

  公开（公告）日：2018-08-02

  The invention relates to a cellobiose phosphorylase, which catalyzes, among other things, the synthesis of cellobiose from glucose 1-phosphate and glucose. The cellobiose phosphorylase according to the invention can be understood as a mutation of the cellobiose phosphorylase from Cellulomonas uda . In comparison to cellobiose phosphorylase of the wild type, the cellobiose phosphorylase according to the invention is distinguished by improved activity and process stability, in particular temperature stability, and lower product inhibition and therefore is especially suitable for use in industrial processes.
• Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome
  申请人：Yamazaki Noboru

  公开号：US20070160657A1

  公开（公告）日：2007-07-12

  An object of the present invention is to provide a liposome having a sugar chain bonded thereto, the sugar chain having an activity of specifically binding to various lectins (sugar chain recognizing proteins) present on the cell surfaces of various tissues and thus being capable of actually distinguishing a cell and a tissue in vivo, thereby efficiently delivering a medicinal drug or a gene.

  本发明的目的是提供一种具有糖链结合的脂质体，该糖链具有特异性结合各种组织细胞表面存在的各种凝集素（糖链识别蛋白），从而能够实际区分体内的细胞和组织，从而有效地传递药物或基因。